Structure Therapeutics (NASDAQ:GPCR – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Profitability
This table compares Structure Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Structure Therapeutics | N/A | -24.91% | -23.67% |
| Oncobiologics | N/A | N/A | -291.28% |
Risk and Volatility
Structure Therapeutics has a beta of -1.35, indicating that its stock price is 235% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Structure Therapeutics | N/A | N/A | -$141.20 million | ($0.87) | -56.19 |
| Oncobiologics | $1.35 million | 168.68 | -$62.42 million | ($1.17) | -1.39 |
Oncobiologics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Structure Therapeutics and Oncobiologics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Structure Therapeutics | 2 | 1 | 12 | 3 | 2.89 |
| Oncobiologics | 1 | 5 | 1 | 0 | 2.00 |
Structure Therapeutics presently has a consensus target price of $110.55, indicating a potential upside of 126.12%. Oncobiologics has a consensus target price of $6.50, indicating a potential upside of 299.75%. Given Oncobiologics’ higher probable upside, analysts clearly believe Oncobiologics is more favorable than Structure Therapeutics.
Institutional and Insider Ownership
91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Structure Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
